Journal of nuclear medicine technology最新文献

{"title":"SNMMI Clinical Trials Network Research Series for Technologists: Imaging Contract Research Organizations, Nuclear Medicine Technologists, and the Role They Play in Medical Imaging Research.","authors":"Matthew C McMahon, Paul Galette","doi":"10.2967/jnmt.123.266111","DOIUrl":"10.2967/jnmt.123.266111","url":null,"abstract":"<p><p>Clinical imaging research is a fast-growing, complex, and integral part of drug and therapy discovery and development. Research sponsors rely on outside vendors to manage their trials and deliver results they hope will demonstrate the efficacy of their product. Specialized vendors known as imaging contract research organizations have teams of highly trained and specialized professionals who lend their expertise to all aspects of imaging research management, of which nuclear medicine technologists are key team members. This article is part of the Clinical Trials Network Research Series for Technologists and will help provide an overview of an imaging research study from initiation to data delivery and the roles that nuclear medicine technologists and other imaging professionals play.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"282-287"},"PeriodicalIF":1.3,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10278109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the Importance of Applying Various Methods of Calculation in Determining the Blood-Absorbed Dose for Patients with Differentiated Thyroid Carcinoma.","authors":"Issa A Al-Shakhrah","doi":"10.2967/jnmt.122.265214","DOIUrl":"10.2967/jnmt.122.265214","url":null,"abstract":"<p><p>The objective was to compare estimated total blood-absorbed doses obtained by applying 4 methods to the same group of patients. In addition, these results were compared with those for the patients of other researchers, who used various other techniques over a period of more than 20 y. <b>Methods:</b> Twenty-seven patients (22 women and 5 men) with differentiated thyroid carcinoma were enrolled in the study. Whole-body measurements were performed as conjugate-view (anterior and posterior) counts by scintillation camera imaging. All patients received 3.7 GBq of ¹³¹I for thyroid ablation. <b>Results:</b> The mean total blood-absorbed doses by the first, second, third, and fourth methods in the 27 patients were estimated to be 0.46 ± 0.12, 0.45 ± 0.13, 0.46 ± 0.19, and 0.62 ± 0.23 Gy, respectively. The maximum values were 1.40, 0.81, 1.04. and 1.33 Gy, respectively. The difference between the mean values was 37.22%. In the comparison with the total blood-absorbed doses for the patients of other researchers, the difference was 50.77% (difference between the means of 0.65 and 0.32 Gy). <b>Conclusion:</b> None of the total absorbed doses to the blood by the 4 methods in my 27 patients was 2 Gy, the maximum permissible dose. The difference between the total absorbed doses to the blood obtained by different teams of researchers was 50.77%, whereas the difference between the values by the 4 different methods in the 27 patients was 37.22%.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"296-301"},"PeriodicalIF":1.3,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9770931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crafting a Compelling Abstract That Gets Accepted.","authors":"Mary Beth Farrell","doi":"10.2967/jnmt.123.266475","DOIUrl":"10.2967/jnmt.123.266475","url":null,"abstract":"<p><p>Presenting an abstract at the Society of Nuclear Medicine and Molecular Imaging annual meeting is an opportunity to gain peer recognition and share knowledge. This article explains how to craft a winning conference abstract. The goal of an abstract is to summarize the main points of a research project or topic. There are 2 types of abstracts: scientific and educational. Scientific abstracts generally involve data collection or a survey and follow a specific formula. The introduction provides a brief background and states the research question. The methods describe the study design and variables. The results present key findings, and the conclusion summarizes the findings' implications and significance. Educational abstracts are unstructured and usually describe a single topic, such as a case study, literature review, or new technique. Crafting an abstract requires clear communication, attention to detail, and an emphasis on practical applications. Effectively structuring a compelling abstract increases your abstract's acceptance chances.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"327-330"},"PeriodicalIF":1.3,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49678547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Season of Celebration.","authors":"Kathy S Thomas","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 4","pages":"265"},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 4","pages":"326"},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SNMMI-TS: 2023 Highlights and a Glimpse into 2024.","authors":"Dmitry D Beyder","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 4","pages":"6A"},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases.","authors":"Austin R Pantel,&nbsp;Matthias Eiber,&nbsp;Dmitry D Beyder,&nbsp;A Tuba Kendi,&nbsp;Richard Laforest,&nbsp;Isabel Rauscher,&nbsp;Edward B Silberstein,&nbsp;Matthew P Thorpe","doi":"10.2967/jnmt.123.265936","DOIUrl":"10.2967/jnmt.123.265936","url":null,"abstract":"University of Pennsylvania, Department of Radiology; School of Medicine, Department of Nuclear Medicine, Technische Universit€at M€unchen, Munich, Germany; Barnes-Jewish Hospital, Department of Radiology; Mayo Clinic Rochester, Department of Radiology; Washington University, Department of Radiology, St. Louis; Technical University of Munich, Department of Nuclear Medicine; and University of Cincinnati Medical Center, Cincinnati","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 3","pages":"176-187"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10168070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Report on the PET/CT Image-Based Radiation Dosimetry of [¹⁸F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer.","authors":"Keisha C McCall,&nbsp;Mofei Liu,&nbsp;Su-Chun Cheng,&nbsp;Amanda Abbott,&nbsp;Shipra Dubey,&nbsp;Diane Young,&nbsp;Mayzie Johnston,&nbsp;Annick D Van den Abbeele,&nbsp;Beth Overmoyer,&nbsp;Heather Jacene","doi":"10.2967/jnmt.123.265623","DOIUrl":"https://doi.org/10.2967/jnmt.123.265623","url":null,"abstract":"<p><p>In a prospective clinical trial, [¹⁸F]fluoro-5α-dihydrotestosterone ([¹⁸F]FDHT), the radiolabeled analog of the androgen dihydrotestosterone, was used as a PET/CT imaging agent for in vivo assessment of metastatic androgen receptor-positive breast cancer in postmenopausal women. To our knowledge, this article presents the first report of PET/CT image-based radiation dosimetry of [¹⁸F]FDHT in women. <b>Methods:</b> [¹⁸F]FDHT PET/CT imaging was performed on a cohort of 11 women at baseline before the start of therapy and at 2 additional time points during selective androgen receptor modulator (SARM) therapy for androgen receptor-positive breast cancer. Volumes of interest (VOIs) were placed over the whole body and within source organs seen on the PET/CT images, and the time-integrated activity coefficients of [¹⁸F]FDHT were derived. The time-integrated activity coefficients for the urinary bladder were calculated using the dynamic urinary bladder model in OLINDA/EXM software, with biologic half-life for urinary excretion derived from VOI measurements of the whole body in postvoid PET/CT images. The time-integrated activity coefficients for all other organs were calculated from VOI measurements in the organs and the physical half-life of ¹⁸F. Organ dose and effective dose calculations were then performed using MIRDcalc, version 1.1. <b>Results:</b> At baseline before SARM therapy, the effective dose for [¹⁸F]FDHT in women was calculated as 0.020 ± 0.0005 mSv/MBq, and the urinary bladder was the organ at risk, with an average absorbed dose of 0.074 ± 0.011 mGy/MBq. Statistically significant decreases in liver SUV or uptake of [¹⁸F]FDHT were found at the 2 additional time points on SARM therapy (linear mixed model, <i>P</i> < 0.05). Likewise, absorbed dose to the liver also decreased by a small but statistically significant amount at the 2 additional time points (linear mixed model, <i>P</i> < 0.05). Neighboring abdominal organs of the gallbladder wall, stomach, pancreas, and adrenals also showed statistically significant decreases in absorbed dose (linear mixed model, <i>P</i> < 0.05). The urinary bladder wall remained the organ at risk at all time points. Absorbed dose to the urinary bladder wall did not show statistically significant changes from baseline at any of the time points (linear mixed model, <i>P</i> ≥ 0.05). Effective dose also did not show statistically significant changes from baseline (linear mixed model, <i>P</i> ≥ 0.05). <b>Conclusion:</b> Effective dose for [¹⁸F]FDHT in women before SARM therapy was calculated as 0.020 ± 0.0005 mSv/MBq. The urinary bladder wall was the organ at risk, with an absorbed dose of 0.074 ± 0.011 mGy/MBq.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 3","pages":"204-210"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FES Whole-Body Imaging Protocol for Evaluating Tumor Estrogen Receptor Status in Patients with Recurrent or Metastatic Breast Cancer.","authors":"Barbara J Grabher","doi":"10.2967/jnmt.122.265272","DOIUrl":"10.2967/jnmt.122.265272","url":null,"abstract":"<p><p>In September 2020, the <i>Journal of Nuclear Medicine and Technology</i> published a continuing education article, \"Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes,\" that reviewed a promising new PET tracer, 16α-¹⁸F-fluoro-17β-fluoroestradiol (¹⁸F-FES). This tracer had the potential to be a valuable tool for medical oncologists and breast surgeons in noninvasively evaluating the estrogen receptor site status of their patients' recurrent tumor and secondary metastatic lesions. In May 2020, ¹⁸F-FES received Food and Drug Administration approval and began being marketed by Zionexa using the trade name Cerianna and manufactured by PETNET. In May 2021, GE Healthcare acquired Zionexa, and Cerianna and is now being marketed by GE Healthcare and is still being manufactured by PETNET. This article will review the ¹⁸F-FES package insert information and imaging protocol, as well as important guidelines for imaging with ¹⁸F-FES.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 3","pages":"188-193"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10538239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Collimators in a High-Resolution, Whole-Body SPECT/CT Device with a Dual-Head Cadmium-Zinc-Telluride Detector for ¹²³I-FP-CIT SPECT.","authors":"Hitoshi Hiraki,&nbsp;Toshimune Ito,&nbsp;Masahisa Onoguchi,&nbsp;Hirotatsu Tsuchikame,&nbsp;Masaaki Shishido,&nbsp;Takafumi Maeno,&nbsp;Takayuki Shibutani,&nbsp;Hiroki Sanada","doi":"10.2967/jnmt.122.265328","DOIUrl":"https://doi.org/10.2967/jnmt.122.265328","url":null,"abstract":"<p><p>The study aim was to evaluate the adaptation of collimators to ¹²³I-<i>N</i>-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)nortropane (¹²³I-FP-CIT) dopamine transporter SPECT (DAT-SPECT) by a high-resolution whole-body SPECT/CT system with a cadmium-zinc-telluride detector (C-SPECT) in terms of image quality, quantitation, diagnostic performance, and acquisition time. <b>Methods:</b> Using a C-SPECT device equipped with a wide-energy, high-resolution collimator and a medium-energy, high-resolution sensitivity (MEHRS) collimator, we evaluated the image quality and quantification of DAT-SPECT for an anthropomorphic striatal phantom. Ordered-subset expectation maximization iterative reconstruction with resolution recovery, scatter, and attenuation correction was used, and the optimal collimator was determined on the basis of the contrast-to-noise ratio (CNR), percentage contrast, and specific binding ratio. The acquisition time that could be reduced using the optimal collimator was determined. The optimal collimator was used to retrospectively evaluate diagnostic accuracy via receiver-operating-characteristic analysis and specific binding ratios for 41 consecutive patients who underwent DAT-SPECT. <b>Results:</b> When the collimators were compared in the phantom verification, the CNR and percentage contrast were significantly higher for the MEHRS collimator than for the wide-energy high-resolution collimator (<i>P</i> < 0.05). There was no significant difference in the CNR between 30 and 15 min of imaging time using the MEHRS collimator. In the clinical study, the areas under the curve for acquisition times of 30 and 15 min were 0.927 and 0.906, respectively, and the diagnostic accuracies of the DAT-SPECT images did not significantly differ between the 2 times. <b>Conclusion:</b> The MEHRS collimator provided the best results for DAT-SPECT with C-SPECT; shorter acquisition times (<15 min) may be possible with injected activity of 167-186 MBq.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 3","pages":"227-234"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10538243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}